Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study
Por:
Borrego, MR, Lopez-Bravo, DP, Vila, MM, Pérez-García, JM, Fernández, M, Tormo, SB, García-Saenz, JA, Lema, L, Garau, I, Cortez, P, Torres, AA, Conejo, EA, Calvo, I, Ferrer, N, Blancas, I, Amillano, K, Santasusagna, S, Benderra, MA, Alcalá-Lopez, D, Antonarelli, G, Sampayo-Cordero, M, Llombart-Cussac, A and Cortés, J
Publicada:
17 ene 2026
Ahead of Print:
1 dic 2025
Resumen:
Introduction Patients with breast cancer (BC) and brain metastases (BMs) have a poor prognosis, particularly those with human epidermal growth factor 2-negative (HER2[-]) BC, including hormone receptor-positive (HR[+]) and triple-negative breast cancer (TNBC). Liposomal irinotecan (nal-IRI) crosses the blood-brain barrier and enhances antitumor activity. Methods PHENOMENAL (NCT03328884) was a single-arm, open-label, multicenter phase 2a study in Spain. Eligible patients had HER2[-] BC with active or stable BMs and prior chemotherapy regimen for metastatic disease (>= 1 taxane line required). Nal-IRI was administered intravenously at 60 mg/m(2) (salt-base) or 50 mg/m(2) (free-base) every 14 days until progression and/or unacceptable toxicity. The primary endpoint was intracranial objective response rate (IC-ORR) in patients with progressive BMs. Key secondary endpoints included ORR, clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Results Fifty-six women (median age 52 years; range, 32-83) were enrolled across 16 sites. Of these, 51.8 % had TNBC, and 91.1 % had progressive BMs at baseline. Median follow-up was 5.7 months (range, 0.4-56.5). The trial achieved its primary endpoint, with IC-ORR of 22.0 % (95 % CI, 11.5-36.0; p < 0.001) among patients with progressive BMs. Median PFS was 1.5 months (95 % CI, 1.4-2.9), while median OS reached 6.4 months (95 % CI, 4.9-10.8). Treatment-emergent adverse events (TEAEs) occurred in 96.4 % of patients; 57.1 % were considered treatment-related and 14.3 % experienced grade >= 3 treatment-related events. Only one patient had a serious treatment-related event, and no treatment-related deaths occurred. Conclusions nal-IRI demonstrated IC activity in HER2[-] BC with BMs. While overall efficacy was limited and long-term outcomes remain poor, these results highlight the unmet need in this challenging population and support the importance of developing more treatment strategies.
Filiaciones:
Borrego, MR:
Hosp Virgen Rocio, Seville, Spain
Lopez-Bravo, DP:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Hosp Santa Creu i St Pau, Oncol Dept, Barcelona, Spain
:
Germans Trias i Pujol Res Inst, Catalan Inst Oncol, Inst Catala Oncol, Med Oncol Serv,B ARGO Res Grp, Carretera Canyet S-N, Badalona 08916, Spain
Pérez-García, JM:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Int Breast Canc Ctr IBCC, Quiron Grp, Pangaea Oncol, Barcelona, Spain
Fernández, M:
Univ Alcala Henares, Hosp Univ Ramon y Cajal, Madrid, Spain
Tormo, SB:
Inst Valenciano Oncol, Valencia, Spain
García-Saenz, JA:
Hosp Univ Clin San Carlos, Madrid, Spain
Lema, L:
Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain
Garau, I:
Hosp Son Llatzer, Palma De Mallorca, Spain
Cortez, P:
Univ Europea, Hosp Ruber Juan Bravo, Madrid, Spain
Torres, AA:
Hosp Univ Miguel Servet, Zaragoza, Spain
Conejo, EA:
Hosp Clin Univ Virgen Victoria, Malaga, Spain
Calvo, I:
MD Anderson Canc Ctr, Breast Canc Unit Oncol, Madrid, Spain
Fdn MD Anderson Int Espana, Madrid, Spain
Ferrer, N:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Blancas, I:
Granada Univ, San Cecilio Univ Hosp, Dept Med, Granada, Spain
Inst Invest Biosanit IBS, Granada, Spain
Amillano, K:
Hosp Univ St Joan Reus, Med Oncol Dept, Reus, Spain
Santasusagna, S:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Benderra, MA:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Alcalá-Lopez, D:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Antonarelli, G:
Natl Canc Inst IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev Innovat Therapies, Milan, Italy
Univ Milan, Dept Oncol & Hemato Oncol DIPO, Milan, Italy
Sampayo-Cordero, M:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Llombart-Cussac, A:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Hosp Arnau Vilanova, FISABIO, Valencia, Spain
Univ Cardenal Herrera CEU, Fac Ciencias Salud, Dept Med, Translat Oncol Grp, Alfara Del Patriarca, Spain
Cortés, J:
Med Scientia Innovat Res MEDSIR, Barcelona, Spain
Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA
Int Breast Canc Ctr IBCC, Quiron Grp, Pangaea Oncol, Barcelona, Spain
Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
Hosp Beata Maria Ana, IOB Madrid, Madrid, Spain
Hosp Univ Torrejon, Oncol Dept, Ribera Grp, Madrid, Spain
|